Risk management across a global supply chain has never been a stronger factor in assuring economic success than it is now.
Emerging pharma hubs are springing up across the world and this provides us with many more options on where to place our valuable assets.
NSF is noticing a trend where a variety of pharma companies want a third-party perspective on the suitability of an outsourcing option, seeking a thorough and impartial assessment of risk, distinctly outside of the influence of internal politics and financial targets.
From such a review, NSF can measure the resource burden of setting up and providing ongoing monitoring of the outsourced location, the inherent risks and how to identify and manage them effectively.
Thank you.Please check your email to download the white paper.